4.7 Article

Synthesis and Characterization of High-Affinity 4, 4-Difluoro-4-bora-3a,4a-diaza-s-indacene-Labeled Fluorescent Ligands for Human β-Adrenoceptors

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 54, 期 19, 页码 6874-6887

出版社

AMER CHEMICAL SOC
DOI: 10.1021/jm2008562

关键词

-

资金

  1. BBSRC [BB/0521581/1]
  2. University of Nottingham
  3. Biotechnology and Biological Sciences Research Council [BB/D521581/1] Funding Source: researchfish
  4. Medical Research Council [G0800006] Funding Source: researchfish
  5. MRC [G0800006] Funding Source: UKRI

向作者/读者索取更多资源

The growing practice of exploiting noninvasive fluorescence-based techniques to study G protein-coupled receptor pharmacology at the single cell and single molecule level demands the availability of high-quality fluorescent ligands. To this end, this study evaluated a new series of red-emitting ligands for the human beta-adrenoceptor family. Upon the basis of the orthosteric ligands propranolol, alprenolol, and pindolol, the synthesized linker-modified congeners were coupled to the commercially available fluorophore BODIPY 630/650-X. This yielded high-affinity beta-adrenoceptor fluorescent ligands for both the propranolol and alprenolol derivatives; however, the pindolol-based products displayed lower affinity. A fluorescent diethylene glycol linked propranolol derivative (18a) had the highest affinity (log K-D of -9.53 and -8.46 as an antagonist of functional beta 2- and beta 1-mediated responses, respectively). Imaging studies with this compound further confirmed that it can be employed to selectively label the human beta 2-adrenoceptor in single living cells, with receptor-associated binding prevented by preincubation with the nonfluorescent beta 2-selective antagonist 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]-butan-2-ol (ICI 118551) (J. Cardiovasc. Pharmacol. 1983, 5,430-437.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

Involvement of β-adrenoceptors in the cardiovascular responses induced by selective adenosine A2A and A2B receptor agonists

Edward S. Wragg, Patrizia Pannucci, Stephen J. Hill, Jeanette Woolard, Samantha L. Cooper

Summary: A(2A) and A(2B) adenosine receptors selectively regulate vascular tone and mean arterial pressure, while inducing tachycardia. The tachycardic response induced by A(2A) or A(2B) receptor stimulation may be mediated by an increase in sympathetic activity. Additionally, the regionally selective effects of A(2B) agonists on vascular conductance are independent of sympathetic activity.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2022)

Article Pharmacology & Pharmacy

Kinetic analysis of endogenous β2-adrenoceptor-mediated cAMP GloSensor™ responses in HEK293 cells

Sean A. Cullum, Dmitry B. Veprintsev, Stephen J. Hill

Summary: This study analysed the kinetic phases of cAMP responses to beta(2)-adrenoceptor agonists in HEK293 cells expressing low levels of endogenous beta(2)-adrenoceptor. It was found that partial agonists had reduced relative IRmax values compared to isoprenaline. Preincubation with beta(2)-adrenoceptor antagonists led to a decrease in the peak response and exacerbated the effect on IRmax values. These findings provide insights into the hemi-equilibria in low receptor reserve systems with agonist-antagonist interactions.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Pharmacology & Pharmacy

Use of NanoBiT and NanoBRET to characterise interleukin-23 receptor dimer formation in living cells

Charles S. Lay, Laura E. Kilpatrick, Peter D. Craggs, Stephen J. Hill

Summary: In this study, the signalling mechanism of IL-23 receptor complexes was explored using NanoBiT and BRET techniques. The results showed that IL-23 receptor complexes formed to the same degree with and without ligand, and signal transduction was induced upon ligand binding. These findings have important implications for drug development targeting the IL-23 receptor.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Biochemistry & Molecular Biology

Plasma membrane preassociation drives (3-arrestin coupling to receptors and activation

Jak Grimes, Zsombor Koszegi, Yann Lanoiselee, Tamara Miljus, Shannon L. O'Brien, Tomasz M. Stepniewski, Brian Medel-Lacruz, Mithu Baidya, Maria Makarova, Ravi Mistry, Joelle Goulding, Julia Drube, Carsten Hoffmann, Dylan M. Owen, Arun K. Shukla, Jana Selent, Stephen J. Hill, Davide Calebiro

Summary: 3-arrestin plays a key role in GPCR signaling and desensitization. This study combines single-molecule microscopy and molecular dynamics simulations to investigate the interactions between 3-arrestin, receptors, and the lipid bilayer. Surprisingly, the results show that 3-arrestin spontaneously inserts into the lipid bilayer and interacts with receptors through lateral diffusion on the plasma membrane. Furthermore, the plasma membrane stabilizes 3-arrestin after receptor interaction, allowing it to separate from the activating receptor and diffuse to clathrin-coated pits. These findings provide new insights into the mechanism of 3-arrestin function at the plasma membrane.
Review Biochemistry & Molecular Biology

COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors

Patrizia Pannucci, Sophie R. Jefferson, Jonathan Hampshire, Samantha L. Cooper, Stephen J. Hill, Jeanette Woolard

Summary: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection responsible for COVID-19 commonly leads to dyspnea and fatigue, primarily affecting the lungs. However, it can also result in dysfunction of extra-pulmonary organs, particularly the cardiovascular system. Cardiac complications such as hypertension, thromboembolism, arrhythmia, and heart failure have been observed in COVID-19 patients, with myocardial injury and myocarditis being the most frequent. Understanding the mechanisms of COVID-19-induced myocarditis, including changes in ACE2 expression and immune responses, is crucial.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Chemistry, Medicinal

Small-Molecule Fluorescent Ligands for the CXCR4 Chemokine Receptor

Sebastian Dekkers, Birgit Caspar, Joelle Goulding, Nicholas D. Kindon, Laura E. Kilpatrick, Leigh A. Stoddart, Stephen J. Briddon, Barrie Kellam, Stephen J. Hill, Michael J. Stocks

Summary: In this study, fluorescent probes based on previously reported small-molecule antagonists were designed and synthesized using classic medicinal chemistry approaches to investigate the pharmacology and cellular distribution of the CXCR4 receptor. Three distinct chemical classes of fluorescent probes were developed and shown to specifically bind to the CXCR4 receptor in a fluorescence-based NanoBRET binding assay (pKD ranging 6.6-7.1). These probes were also used in competition binding experiments and confocal microscopy to further explore the pharmacology and cellular distribution of CXCR4.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Rapid Elaboration of Fragments into Leads Applied to Bromodomain-3 Extra-Terminal Domain

Luke A. Adams, Lorna E. Wilkinson-White, Menachem J. Gunzburg, Stephen J. Headey, Biswaranjan Mohanty, Martin J. Scanlon, Ben Capuano, Joel P. Mackay, Bradley C. Doak

Summary: A systematic workflow, called Rapid Elaboration of Fragments into Leads (REFiL), allows for the rapid improvement of binding affinity and evolution of low-affinity fragment hits into higher-affinity leads without the need for structural information.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Multidisciplinary Sciences

Characterisation of IL-23 receptor antagonists and disease relevant mutants using fluorescent probes

Charles S. Lay, Albert Isidro-Llobet, Laura E. Kilpatrick, Peter D. Craggs, Stephen J. Hill

Summary: Using a fluorescent version of IL-23, this study characterized antagonists of the full-length receptor expressed by living cells and developed a cyclic peptide fluorescent probe specific to the IL23p19:IL23R interface to further study receptor antagonists. The study also demonstrated that the immunocompromising C115Y IL23R mutation disrupts the binding epitope for IL23p19.

NATURE COMMUNICATIONS (2023)

Article Pharmacology & Pharmacy

Characterisation of tyrosine kinase inhibitor-receptor interactions at VEGFR2 using sunitinib-red and nanoBRET

Marieke Van Daele, Laura E. Kilpatrick, Jeanette Woolard, Stephen J. Hill

Summary: Vascular endothelial growth factor (VEGF) is crucial for angiogenesis and vascular endothelial cell functions. The study developed a ligand-binding assay to monitor the binding affinity and kinetics of different tyrosine kinase inhibitors (TKIs) to VEGF receptor 2 (VEGFR2). The results showed that compounds inhibiting the binding of a fluorescent analogue of sunitinib (sunitinib-red) also attenuated VEGFR2-mediated signaling, suggesting potential cardiovascular liabilities.

BIOCHEMICAL PHARMACOLOGY (2023)

Review Pharmacology & Pharmacy

Kinetic analysis of fluorescent ligand binding to cell surface receptors: Insights into conformational changes and allosterism in living cells

Stephen J. Hill, Laura E. Kilpatrick

Summary: Equilibrium binding assays are commonly used in drug discovery to evaluate drug-receptor interactions, but there is increasing interest in studying the kinetics of these interactions. Drugs can induce conformational changes in the orthosteric binding site, leading to alterations in the association and dissociation rates of orthosteric ligands. This review provides an overview of how fluorescent ligand technologies are used to study ligand-receptor kinetics in living cells and the insights they offer into conformational changes induced by drugs targeting cell surface receptors.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Chemistry, Medicinal

Design, Synthesis, and Application of Fluorescent Ligands Targeting the Intracellular Allosteric Binding Site of the CXC Chemokine Receptor 2

Bianca Maria Casella, James P. P. Farmer, Desislava N. N. Nesheva, Huw E. L. Williams, Steven J. J. Charlton, Nicholas D. D. Holliday, Charles A. A. Laughton, Shailesh N. N. Mistry

Summary: Inhibition of CXCR2 is a potential strategy for the treatment of pulmonary diseases and cancers. This study reports the design and synthesis of fluorescent NAMs that selectively bind to CXCR2, enabling the measurement and evaluation of their pharmacological properties. These NAMs can be used as alternative compounds for targeting these receptors.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Multidisciplinary Sciences

Probing expression of E-selectin using CRISPR-Cas9-mediated tagging with HiBiT in human endothelial cells

Lydia Ogrodzinski, Simon Platt, Joelle Goulding, Cameron Alexander, Tracy D. Farr, Jeanette Woolard, Stephen J. Hill, Laura E. Kilpatrick

Summary: E-selectin is a protein expressed on endothelial cells in response to inflammatory cytokines, and it plays a role in leukocyte rolling and extravasation. This study used CRISPR-Cas9 genome editing and NanoLuc Binary Technology (NanoBiT) to tag endogenous E-selectin in human umbilical vein endothelial cells (HUVECs) and monitor its expression in real time. The combination of NanoBiT and CRISPR-Cas9 gene editing provides a powerful tool for monitoring dynamic changes in E-selectin expression on cell surfaces, which can contribute to the discovery of drugs targeting this important inflammatory protein.

ISCIENCE (2023)

Article Hematology

Characterizing the binding of glycoprotein VI with nanobody 35 reveals a novel monomeric structure of glycoprotein VI where the conformation of D1+D2 is independent of dimerization

Foteini-Nafsika Damaskinaki, Natalie J. Jooss, Eleyna M. Martin, Joanne C. Clark, Mark R. Thomas, Natalie S. Poulter, Jonas Emsley, Barrie Kellam, Steve P. Watson, Alexandre Slater

Summary: This study investigates the binding sites of three high-affinity nanobodies, Nb2, Nb21, and Nb35, on the platelet-signaling receptor GPVI. The researchers found that all three nanobodies can bind to the D1 domain of GPVI and inhibit collagen-induced GPVI signaling. They also identified common target residues, Arg46, Tyr47, and Ala57, on GPVI for these nanobodies. Additionally, the study negates the idea that GPVI dimerization induces a conformational change required for ligand binding.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Meeting Abstract Pharmacology & Pharmacy

A fluorescent G protein mimetic peptide probe for high-throughput characterisation of intracellular allosteric modulator binding and GPCR activation

James Farmer, Nicholas Holliday, Shailesh Mistry, Charles Laughton

BRITISH JOURNAL OF PHARMACOLOGY (2023)

暂无数据